Lantus Missed-Dose Protocol: What to Do When You Skip Insulin Glargine

How Insulin Glargine Works: The Pharmacokinetic Basis for Missed-Dose Decisions

Insulin glargine is a modified human insulin analog where two arginine residues are added to the B-chain C-terminus and asparagine at position A21 is replaced with glycine. These changes shift the isoelectric point to pH 4.0, making the solution clear and acidic in the vial but causing microprecipitation at physiologic pH 7.4 after subcutaneous injection 1. The microprecipitates dissolve slowly, creating a near-peakless insulin release over approximately 20-24 hours.

This depot pharmacology matters for missed-dose reasoning. Because glargine has no sharp concentration spike, a delayed injection creates a gradual insulin deficit rather than an abrupt one. Blood glucose rises predictably at roughly 3-5 mg/dL per hour once the previous dose's tail dissipates 2. The clinical consequence: you have a wider corrective window than with NPH or premixed insulins, but the window is not unlimited.

The ORIGIN trial (N=12,537) demonstrated that insulin glargine titrated to a fasting glucose target of ≤95 mg/dL produced neutral cardiovascular outcomes (HR 1.02 to 95% CI 0.94-1.11) over a median 6.2 years of follow-up 3. Severe hypoglycemia occurred at 5.9 events per 100 patient-years, lower than rates seen with more aggressive regimens. This safety profile supports conservative dose-recovery strategies rather than aggressive compensation.

The 8-Hour Rule: A Practical Threshold

The Sanofi prescribing information for Lantus states that if a dose is missed, patients should not double their next injection 4. The label does not specify a precise time threshold, but endocrinology consensus and clinical practice guidelines from the American Diabetes Association coalesce around an 8-hour dividing line.

If fewer than 8 hours have elapsed since your scheduled injection time: administer your full prescribed dose. Resume your normal schedule the following day. Your basal coverage gap has been brief enough that full-dose replacement is both safe and necessary.

If 8-12 hours have elapsed: contact your prescriber for individualized guidance. A common recommendation is 50-75% of the usual dose, with a return to full dosing at the next scheduled time. This partial-dose approach reduces stacking risk while partially restoring basal coverage.

If more than 12 hours have elapsed: many clinicians recommend skipping entirely and resuming at the next scheduled time, particularly for patients at elevated hypoglycemia risk (age >65, eGFR <45 mL/min, concurrent sulfonylurea use). Blood glucose monitoring every 2-4 hours during the coverage gap is standard practice.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington and editor of multiple ADA clinical guidelines, has stated: "The biggest mistake patients make with basal insulin is panic-dosing after a missed injection. A single missed dose of glargine will not cause DKA in type 2 diabetes. The real danger is the hypoglycemia from doubling up."

Why You Should Never Double the Next Dose

Stacking basal insulin (injecting two doses within a compressed timeframe) creates overlapping pharmacokinetic tails. Glargine's 20-24 hour duration means that a double dose delivers roughly 180-200% of intended basal coverage during the overlap period. A 2015 analysis of insulin dosing errors reported to the FDA Adverse Event Reporting System found that accidental double-dosing of long-acting insulin accounted for 11.4% of serious hypoglycemia reports requiring emergency department visits 5.

Severe hypoglycemia (glucose <54 mg/dL) carries immediate risks including seizure, loss of consciousness, and cardiac arrhythmia. The ADA Standards of Care 2024 grade severe hypoglycemia as a clinical emergency requiring glucagon administration 6.

The risk escalates in specific populations. Patients taking sulfonylureas alongside basal insulin face compounded hypoglycemia risk. Those with chronic kidney disease (stage 3b or worse) clear insulin more slowly, extending the effective duration beyond 24 hours. Older adults with impaired counter-regulatory hormone responses may not experience typical warning symptoms before neuroglycopenic events.

Adjusting Your Schedule After a Missed Dose

A single late injection does not require permanent schedule restructuring. Resume at your original time the following day. The brief asymmetry in coverage (a slightly shorter interval followed by a slightly longer one) produces minimal glycemic disruption for most patients 7.

If you frequently miss your scheduled time, consider switching your injection to a different time of day. Glargine can be administered at any consistent time. Morning dosing correlates with better adherence in shift workers. Evening dosing may produce slightly lower fasting glucose in some individuals, though the INSIGHT study found no clinically significant difference in A1C between morning and evening administration (7.03% vs. 6.96%, P=0.47) 8.

For patients who miss doses more than twice monthly, the 2022 ADA/EASD consensus report recommends evaluating barriers to adherence including injection burden, cost, needle phobia, and regimen complexity 9. Switching to a weekly basal insulin (insulin icodec, approved as Awiqli in 2024) may reduce missed-dose frequency by 75% based on ONWARDS trial data.

Monitoring Blood Glucose During a Coverage Gap

When basal insulin coverage lapses, structured glucose monitoring becomes your safety net. The minimum protocol during a missed-dose period:

Check fasting glucose upon waking. Check again 4 hours after the missed dose window. Check before each meal. Check at bedtime. If any reading exceeds 250 mg/dL in a patient with type 1 diabetes, check urine or blood ketones immediately. For type 2 patients, the ketone threshold is 300 mg/dL.

Continuous glucose monitoring (CGM) users have an advantage here. The Dexcom G7 and Libre 3 provide real-time trending that shows the rate of glucose rise during the basal gap. A rise exceeding 3 mg/dL per minute (shown as a steep upward arrow) warrants correction with rapid-acting insulin per your prescriber's sliding scale 10.

The 2023 international consensus on CGM use in diabetes recommends a time-in-range target of >70% (glucose 70-180 mg/dL) over any rolling 14-day period 11. A single missed basal dose typically reduces 24-hour time-in-range by 8-15 percentage points, recoverable within 48-72 hours of resumed dosing.

Special Populations: Type 1 Diabetes and DKA Risk

The missed-dose calculus differs between type 1 and type 2 diabetes. Type 1 patients produce no endogenous insulin. A fully missed basal dose can precipitate diabetic ketoacidosis (DKA) within 8-12 hours, particularly if the patient also skips bolus insulin 12.

The ADA Position Statement on DKA identifies insulin omission as the leading precipitant of DKA admissions, accounting for 44% of cases in adults with type 1 diabetes. Symptoms begin with polyuria and polydipsia, progress to nausea and abdominal pain, and can advance to altered consciousness within hours.

For type 1 patients who realize they missed their glargine dose: inject immediately regardless of how many hours have passed. A late full dose carries less risk than no dose. Simultaneously check blood ketones. If beta-hydroxybutyrate exceeds 1.5 mmol/L, initiate your sick-day protocol and contact your endocrinologist.

Type 2 patients with substantial residual beta-cell function face lower acute risk from a single missed dose. Endogenous insulin secretion partially compensates, and DKA is uncommon unless concurrent illness, steroid use, or SGLT2 inhibitor therapy is present.

Injection Site and Absorption Considerations

Where you inject affects how quickly the depot forms and dissolves. The abdomen provides the fastest and most consistent absorption. The thigh produces slightly slower absorption with a longer tail. The upper arm falls between. These differences become clinically relevant during dose recovery.

If administering a late dose, inject in the abdomen to achieve peak effect sooner. Avoid injecting into areas with lipohypertrophy (thickened fatty tissue from repeated injection at the same site), which can delay absorption by 25-50% and increase glycemic variability 13.

A 2016 systematic review of injection technique studies found that lipohypertrophy affected 38% of insulin-using patients and was independently associated with unexplained hypoglycemia and glucose variability. Rotating injection sites within a body region (using a clock-pattern or grid approach) reduces lipohypertrophy development.

Biosimilars and Interchangeability

Insulin glargine is available as the originator product (Lantus) and as biosimilars including Basaglar (Eli Lilly), Semglee (Mylan/Viatris), and Rezvoglar (Eli Lilly). The FDA designated Semglee as the first interchangeable biosimilar insulin in 2021, meaning pharmacists can substitute it without prescriber authorization in most states 14.

All glargine products share identical pharmacokinetics. The missed-dose protocol applies equally regardless of which brand you use. Switching between products mid-treatment does not alter the timing rules. The 100 units/mL formulations (U-100) and the concentrated 300 units/mL formulation (Toujeo) differ in duration, with Toujeo providing approximately 30-32 hours of coverage due to a smaller subcutaneous depot surface area.

For Toujeo (glargine U-300) specifically, the longer duration provides more forgiveness for late doses. Patients on Toujeo who are fewer than 12 hours late can generally take their full dose without adjustment. The BRIGHT study confirmed that Toujeo produced 23% less hypoglycemia than Lantus U-100 during the titration phase, partly attributable to its flatter pharmacokinetic profile 15.

When to Seek Emergency Care

Most missed-dose situations resolve with home management. Seek emergency care if:

Blood glucose exceeds 400 mg/dL despite correction insulin. Blood or urine ketones are moderate-to-large (beta-hydroxybutyrate >3.0 mmol/L). You experience persistent vomiting preventing oral hydration. You develop rapid breathing, fruity breath odor, or confusion. You accidentally administered a double dose and glucose falls below 54 mg/dL despite oral carbohydrate intake.

The Endocrine Society Clinical Practice Guideline on hypoglycemia management recommends intramuscular glucagon (1 mg) or nasal glucagon (3 mg, Baqsimi) for any episode producing loss of consciousness or inability to swallow 16. Every household with an insulin-using patient should stock unexpired glucagon.